Thelansis

Acanthamoeba Keratitis (AK) Market Outlook Thelansis’s “Acanthamoeba Keratitis (AK) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acanthamoeba Keratitis (AK) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the mar...

Acanthamoeba Keratitis (AK) Market Outlook Thelansis’s “Acanthamoeba Keratitis (AK) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acanthamoeba Keratitis (AK)     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Acanthamoeba Keratitis (AK) Overview Acanthamoeba keratitis (AK), a rare and challenging cornea infection to diagnose and treat effectively, is caused by various genotypes of the Acanthamoeba organism, classified as T1–T22 based on 18s rRNA gene typing. Clinical presentation and treatment response vary depending on the genotype. Transmission occurs through corneal contact with contaminated substances, with human ca...

 Acanthamoeba keratitis (AK), a rare and challenging cornea infection to diagnose and treat effectively, is caused by various genotypes of the Acanthamoeba organism, classified as T1–T22 based on 18s rRNA gene typing. Clinical presentation and treatment response vary depending on the genotype. Transmission occurs through corneal contact with contaminated substances, with human cases often linked to tainted water, soil, or eye trauma. The disease progresses through two phases: an initial phase affecting only the corneal epithelium, followed by invasion into the underlying stroma, resulting in significant damage to the collagen matrix and triggering intense inflammation. AKANTIOR® (polihexanide), a novel anti-amoebic polymer, holds promise as the first approved drug for treating Acanthamoeba keratitis worldwide. Polihexanide targets both trophozoites and cysts of the Acanthamoeba protozoan. ·        The estimated incidence of Acanthamoeba keratitis (AK...

 Acanthamoeba keratitis (AK) is a rare cornea infection that is difficult to diagnose and treat properly. It can be a sight-threatening disease. Acanthamoeba is currently divided into twenty-two different genotypes (T1–T22) based on 18s rRNA gene typing. Based on genotype variations, clinical presentation and response to therapy vary. The pathogen is transmitted through corneal contact with a contaminated substance. Most cases seen in humans seem to be associated with contaminated water, soil, or trauma to the eye. The progression of Acanthamoeba keratitis occurs in two main phases. An initial phase where infiltration is limited to the corneal epithelium, and a second phase where the parasite invades the underlying stroma. Once in the stroma, extensive damage to the collagen matrix occurs, which provokes intense inflammation. ·        The estimated incidence of Acanthamoeba keratitis (AK) cases with soft contact lens wearers ranges between 4.5 to 7.8...

  Acanthamoeba keratitis (AK) is a rare infection of the cornea that, difficult to diagnose and treat properly, can be a sight-threatening disease. Acanthamoeba is currently divided into twenty-two different genotypes (T1–T22) based on 18s rRNA gene typing. Based on genotypes variations clinical presentation and response to therapy vary. The pathogen is transmitted through corneal contact with a contaminated substance. Most cases seen in humans seem to be associated with contaminated water, soil, or trauma to the eye. The progression of Acanthamoeba keratitis occurs in two main phases. An initial phase where infiltration is limited to the corneal epithelium, and a second phase where the parasite invades the underlying stroma. Once in the stroma, extensive damage to the collagen matrix occurs which provokes intense inflammation. The estimated incidence of cases of Acanthamoeba keratitis with soft contact lens wearers ranges between 4.5 to 7.8 cases per 100,000 population.  ...